SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics

/PRNewswire/ -- SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce...

Related Keywords

Shanghai ,China ,United States ,American ,Mary Lowell Leary ,Mayo Clinic Neuroregeneration Lab ,Mayo Clinic Alzheimer Disease Research Center ,Washington University School Of Medicine ,Eli Lilly Co ,Department Of Neuroscience ,Prnewswire Scineuro Pharmaceuticals ,American Association For The Advancement Of Science ,Alzheimer Association ,Scineuro Pharmaceuticals ,Mayo Clinic ,Alpha Synuclein Inhibitor ,Neuro Pharmaceuticals ,Chief Scientific ,Chief Scientific Officer ,Mary Lowell Leary Professor ,Associate Director ,Mayo Clinic Alzheimer ,Disease Research ,Cell Biology ,Washington University School ,Molecular Neurodegeneration ,Associate Editor ,Science Advances ,Advisory Board ,American Association ,Zenith Fellows Award ,Metlife Award ,Medical Research ,Eli Lilly ,Press Release ,